Aurinia Pharmaceuticals Inc Senior Officer Neil Solomons Sells 10,000 Shares

Aurinia Pharmaceuticals Inc Senior Officer Neil Solomons sold 10,000 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of C$8.53, for a total transaction of C$85,279.00. Following the transaction, the insider now directly owns 287,999 shares in the company, valued at C$2,456,026.67.

Neil Solomons also recently made the following trade(s):

  • On Thursday, April 25th, Neil Solomons sold 34,733 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of C$8.44, for a total transaction of C$293,285.45.
  • Shares of AUP stock traded up C$0.20 during mid-day trading on Friday, reaching C$8.48. 42,200 shares of the company’s stock traded hands, compared to its average volume of 73,789. The stock has a market cap of $774.32 million and a PE ratio of -11.22. Aurinia Pharmaceuticals Inc has a 12 month low of C$6.60 and a 12 month high of C$10.47.
  • Aurinia Pharmaceuticals last issued its earnings results on Tuesday, March 19th. The company reported C($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.19) by C($0.04). The business had revenue of C$0.04 million during the quarter, compared to analyst estimates of C$0.09 million. Equities research analysts expect that Aurinia Pharmaceuticals Inc will post -0.280000013254438 earnings per share for the current year.

Several analysts recently weighed in on AUP shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, March 20th. Svb Leerink reiterated an “outperform” rating on shares of Aurinia Pharmaceuticals in a report on Tuesday, March 19th.

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

, , , ,